<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004326" GROUP_ID="ENT" ID="014399092916553049" MERGED_FROM="" MODIFIED="2008-11-12 14:11:42 +0100" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-12 13:05:38 +0000" NOTES_MODIFIED_BY="Jenny Bellorini" REVIEW_NO="0037" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-11-12 14:11:42 +0100" MODIFIED_BY="Jenny Bellorini">
<TITLE>Ear drops for the removal of ear wax</TITLE>
<CONTACT MODIFIED="2008-11-12 14:11:42 +0100" MODIFIED_BY="Jenny Bellorini"><PERSON ID="BE67C2AB82E26AA2014A5594476783BD" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Martin</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Burton</LAST_NAME><POSITION>Consultant Otolaryngologist</POSITION><EMAIL_1>mburton@cochrane-ent.org</EMAIL_1><ADDRESS><DEPARTMENT>Department of Otolaryngology - Head and Neck Surgery</DEPARTMENT><ORGANISATION>Oxford Radcliffe Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Level LG1, West Wing</ADDRESS_1><ADDRESS_2>John Radcliffe Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 231051</PHONE_1><FAX_1>+44 1865 231091</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-12 14:11:42 +0100" MODIFIED_BY="Jenny Bellorini"><PERSON ID="BE67C2AB82E26AA2014A5594476783BD" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Martin</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Burton</LAST_NAME><POSITION>Consultant Otolaryngologist</POSITION><EMAIL_1>mburton@cochrane-ent.org</EMAIL_1><ADDRESS><DEPARTMENT>Department of Otolaryngology - Head and Neck Surgery</DEPARTMENT><ORGANISATION>Oxford Radcliffe Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Level LG1, West Wing</ADDRESS_1><ADDRESS_2>John Radcliffe Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 231051</PHONE_1><FAX_1>+44 1865 231091</FAX_1></ADDRESS></PERSON><PERSON ID="13392" ROLE="AUTHOR"><FIRST_NAME>Carolyn</FIRST_NAME><LAST_NAME>Doree</LAST_NAME><POSITION>Information Specialist</POSITION><EMAIL_1>carolyn.doree@nhsbt.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Systematic Review Initiative</DEPARTMENT><ORGANISATION>NHS Blood and Transplant</ORGANISATION><ADDRESS_1>John Radcliffe Hospital</ADDRESS_1><CITY>Oxford</CITY><ZIP>OX3 9BQ</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-12 13:03:03 +0000" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;Minor update: 5/22/07&lt;/p&gt;" NOTES_MODIFIED="2008-11-12 13:03:03 +0000" NOTES_MODIFIED_BY="Jenny Bellorini">
<UP_TO_DATE>
<DATE DAY="22" MONTH="4" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="4" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="21" MONTH="4" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-12 13:05:38 +0000" MODIFIED_BY="Jenny Bellorini">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-11-12 13:02:19 +0000" MODIFIED_BY="Jenny Bellorini">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>New searches conducted 23 April 2008. One additional new study identified (<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>). Conclusion changed following inclusion of new study.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-12 13:05:38 +0000" MODIFIED_BY="Jenny Bellorini">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-12 13:05:38 +0000" MODIFIED_BY="Jenny Bellorini">
<DATE DAY="22" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-11-12 13:01:20 +0000" MODIFIED_BY="Jenny Bellorini">
<DATE DAY="5" MONTH="12" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-12 13:01:10 +0000" MODIFIED_BY="Jenny Bellorini">
<SUMMARY MODIFIED="2008-05-13 11:14:32 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-13 11:14:32 +0100" MODIFIED_BY="[Empty name]">Using ear drops to remove impacted ear wax is better than no treatment, but no particular sort of drops can be recommended over any other</TITLE>
<SUMMARY_BODY>
<P>Impacted ear wax is one of the most common reasons that people visit their general practitioners (family doctors) with ear problems, as it can cause reduced hearing, discomfort, and sometimes pain and dizziness. Ear drops (either oil- or water-based) are often prescribed to clear the wax or to aid subsequent ear syringing if necessary. The review of trials found that ear drops (of any sort) can help to remove ear wax, but that water and saline drops appear to be as good as more costly commercial products. The quality of the trials was generally low, however, and more research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-12 13:01:10 +0000" MODIFIED_BY="Jenny Bellorini">
<ABS_BACKGROUND MODIFIED="2008-11-12 13:01:10 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Problems attributed to the accumulation of wax (cerumen) are among the most common reasons for people to present to their general practitioners with ear trouble. Treatment for this condition often involves use of a wax softening agent (cerumenolytic) to disperse the cerumen, reduce the need for, or facilitate syringing, but there is no consensus on the effectiveness of the variety of cerumenolytics in use.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effectiveness of ear drops (cerumenolytics) for the removal of symptomatic ear wax.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-12 13:00:58 +0000" MODIFIED_BY="Jenny Bellorini">
<P>We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, 2008 issue 2); MEDLINE; EMBASE; CINAHL; ISI Proceedings; Cambridge Scientific Abstracts; mRCT and additional sources for published and unpublished trials. The date of the most recent search was April 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-05-13 11:12:28 +0100" MODIFIED_BY="[Empty name]">
<P>We identified all randomised controlled trials in which a cerumenolytic was compared with no treatment, a placebo, or other cerumenolytics in participants with obstructing or impacted ear wax, and in which the proportion of participants with sufficient clearance of the external canal to make further mechanical clearance unnecessary (primary outcome measure) was stated or calculable. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-05-13 11:12:59 +0100" MODIFIED_BY="[Empty name]">
<P>The two authors reviewed all the retrieved trials and applied the inclusion criteria independently.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-12 11:56:26 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Nine trials satisfied the inclusion criteria. In all, 679 participants received one of 11 different cerumenolytics. One trial compared active treatments with no treatment, three compared active treatments with water or a saline 'placebo', and all nine trials compared two or more active treatments. Eight trials included syringing as a secondary intervention.</P>
<P>Overall, results were inconclusive. The majority of comparisons showed no difference between treatments.  Meta-analysis of two high quality trials produced a statistical difference in favour of triethanolamine polypeptide over saline in preventing the need for syringing, but no other significant differences between treatments.</P>
<P>In three trials of high to moderate quality, no difference was found between the effectiveness of either sodium bicarbonate ear drops, chlorbutanol, triethanolamine polypeptide oleate condensate or docusate sodium liquid versus a sterile water or saline 'placebo'.</P>
<P>One trial of moderate methodological quality found all three treatments - sodium bicarbonate ear drops, chlorbutanol and sterile water - to be significantly better than no treatment at preventing the need for syringing.</P>
<P>None of the higher quality trials demonstrated superiority of one agent over another in direct comparisons.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-05-14 09:58:29 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Trials have been heterogeneous and generally of low or moderate quality, making it difficult to offer any definitive recommendations on the effectiveness of cerumenolytics for the removal of symptomatic ear wax. Using drops of any sort appears to be better than no treatment, but it is uncertain if one type of drop is any better than another. Future trials should be of high methodological quality, have large sample sizes, and compare both oil-based and water-based solvents with placebo, no treatment or both.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-12 13:00:18 +0000" MODIFIED_BY="Jenny Bellorini">
<BACKGROUND MODIFIED="2008-11-12 13:00:18 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Problems attributed to the accumulation of wax are one of the most common reasons for people to present to their general practitioner (GP) with ear trouble. Ear wax removal is the most common otolaryngological procedure performed in primary care. In 1990 the average GP carried this out almost twice a week (<LINK REF="REF-Sharp-1990" TYPE="REFERENCE">Sharp 1990</LINK>); nowadays in the United Kingdom the procedure is usually performed by nursing staff. People presenting with excessive wax in the ears therefore take up a significant proportion of GPs' consultation time.</P>
<P>The external auditory canal is divided into two parts, the lateral cartilaginous portion (outer two-thirds) and the medial bony portion (inner one-third). The skin lining the inner bony meatus is only 0.1 mm thick and is tightly attached to the underlying bone and to the squamo-tympanic suture. It has no special function other than protection and clearance of desquamating keratin by migration. The skin lining the outer two-thirds of the canal is 10 to 15 times thicker and has a well-developed subcutaneous layer which contains hair follicles, ceruminous glands (slightly modified sweat glands) and sebaceous glands (which open into the hair follicles). Ear wax, or cerumen, is a mixture of the secretion of these two types of glands and the exfoliated squamous epithelium (which is the major component). Cerumen also contains glycopeptides, lipids, hyaluronic acid, sialic acid, lysosomal enzymes and immunoglobulins, and exerts a protective, antibacterial effect by helping to maintain an acidic condition in the external auditory canal whilst also lubricating and protecting the ear canal (<LINK REF="STD-Carr-2001" TYPE="STUDY">Carr 2001</LINK>; <LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>). It has a pH of 5.2 to 7.0. Normally the wax, dust and dirt migrate in a lateral direction, the movement of the jaw contributing to this migration. The wax then passes on to the skin of the outer ear (auricle), where it dries and disappears, having achieved its aim of removing dust and destroying bacteria and fungi.</P>
<P>This self cleaning mechanism sometimes fails, however, causing retention or even impaction of wax. Cerumen impaction is more common in the elderly because as a person ages the cerumen glands atrophy, increasing the tendency of the cerumen to become drier. This may lead to cerumen build up and oxidation. Recent surveys examining the prevalence of impacted wax (<LINK REF="REF-Kalantan-1999" TYPE="REFERENCE">Kalantan 1999</LINK>; <LINK REF="REF-Lewis_x002d_Cullinan-1990" TYPE="REFERENCE">Lewis-Cullinan 1990</LINK>; <LINK REF="REF-Minja-1996" TYPE="REFERENCE">Minja 1996</LINK>; <LINK REF="REF-Swart-1995" TYPE="REFERENCE">Swart 1995</LINK>) suggest that it is higher in men than in women, in the elderly than in the young, and in people with intellectual impairment (<LINK REF="REF-Brister-1990" TYPE="REFERENCE">Brister 1990</LINK>). Other factors that prevent the normal extrusion of wax from the ear canal (e.g. wearing a hearing aid, or using cotton buds) can further increase the chance of ear wax accumulating, while people with narrow or deformed ear canals or dermatologic disease of the periauricular skin or scalp are also susceptible to cerumen impaction.</P>
<P>All these factors show that the development of an occluding wax plug is not associated with personal hygiene, but is rather a constitutional and unpreventable condition. Nevertheless, a common cause of excessive cerumen accumulation remains misguided attempts to remove wax with such instruments as cotton swabs, needles and hair pins which, besides traumatising the skin, often contribute to impaction and can impair the cleansing mechanism.</P>
<P>Ear wax is thus a normal secretion which becomes a problem in certain circumstances. The accumulation of wax has several sequelae: (a) it can interfere with the clinician's view of the tympanic membrane; (b) it can cause a conductive hearing loss and hence may interfere with formal hearing assessment; (c) if in contact with the tympanic membrane it can cause discomfort and occasionally vertigo; and (d) it can contribute to infection (<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>).<BR/>
<BR/>Although topical emollients have been proposed for the prevention of ear wax accumulation (<LINK REF="REF-Saloranta-2001" TYPE="REFERENCE">Saloranta 2001</LINK>), they are not widely used. However, there are a number of ways of dislodging and extracting impacted cerumen, including the use of ear syringing or irrigation (in which wax is washed out of the ear canal by a jet of warm water), other manual removal methods (such as ear curettes for hooking out the wax, or micro-suction), and two basic kinds of ear wax solvents - those based on oils which soften the wax by dissolution, and those based on aqueous systems which improve water miscibility. A combination of the above may be used. (Alternative medical therapies such as ear candling have been shown to be ineffective (<LINK REF="REF-Seely-1996" TYPE="REFERENCE">Seely 1996</LINK>)).</P>
<P>Cerumen removal is not without potential hazards. From the results of a survey of 105 general practitioners, <LINK REF="REF-Sharp-1990" TYPE="REFERENCE">Sharp 1990</LINK> lists specific complications of cerumen management as follows - failure of wax removal; pain; tinnitus, or vertigo; otitis media or otitis externa; damage to the skin of the external canal; and perforation of the tympanic membrane. Other complications include bleeding (which is usually self-limited), infection, or disturbance in balance causing nausea and vomiting (<LINK REF="REF-Dinsdale-1991" TYPE="REFERENCE">Dinsdale 1991</LINK>; <LINK REF="REF-Grossan-2000" TYPE="REFERENCE">Grossan 2000</LINK>; <LINK REF="REF-Zikk-1991" TYPE="REFERENCE">Zikk 1991</LINK>; <LINK REF="REF-Zivic-1993" TYPE="REFERENCE">Zivic 1993</LINK>). There have even been rare deaths associated with syringe irrigation (<LINK REF="REF-Prasad-1984" TYPE="REFERENCE">Prasad 1984</LINK>), and complications occur in about 1 in 1000 ears syringed (<LINK REF="REF-Sharp-1990" TYPE="REFERENCE">Sharp 1990</LINK>). Ear syringing is contraindicated if the ear drum is perforated, if there is a history of mastoid surgery or chronic middle ear disease, or if the person has unilateral deafness (i.e. the ear in question is the person's only hearing ear). Caution is also advised if there is a history of recurrent otitis externa or tinnitus, as it may aggravate these conditions. Thus, each of these methods of ear wax removal has potential complications, and requires a significant amount of time and effort on the part of a health care professional, who may have received little or no training for the task.</P>
<P>Although there is consensus that the use of cerumenolytics (with or without ear syringing) is effective, no systematic review was found examining the efficacy of this or other interventions commonly used for the treatment of impacted wax. A systematic review of published clinical trials was therefore proposed, using established meta-analysis techniques.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the clinical effectiveness of ear drops for the removal of symptomatic ear wax.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-12 12:59:37 +0000" MODIFIED_BY="Jenny Bellorini">
<SELECTION_CRITERIA MODIFIED="2008-11-12 12:59:37 +0000" MODIFIED_BY="Jenny Bellorini">
<CRIT_STUDIES MODIFIED="2008-11-12 12:59:37 +0000" MODIFIED_BY="Jenny Bellorini">
<P>We included all identified randomised controlled trials which fulfilled the criteria outlined below. We also identified controlled clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-12 12:59:08 +0000" MODIFIED_BY="Jenny Bellorini">
<P>We included adults or children diagnosed as having ear wax which required removal. The need to remove the wax was determined by primary care physicians or specialists.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Topical preparations including commercially produced cerumenolytics, hydrogen peroxide, olive oil or almond oil, sodium bicarbonate, water or any other topical preparation.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-12 12:58:52 +0000" MODIFIED_BY="Jenny Bellorini">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-12 12:58:50 +0000" MODIFIED_BY="Jenny Bellorini">
<UL>
<LI>Proportion of participants with sufficient clearance of the external canal, as determined by otoscopy, to make further mechanical clearance unnecessary.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-12 12:58:52 +0000" MODIFIED_BY="Jenny Bellorini">
<UL>
<LI>Ease of mechanical removal (measured, for example, by the volume of water used to accomplish successful syringing, speed, or similar appropriate validated measures).</LI>
<LI>Extent of wax removal.</LI>
<LI>Proportion of people (or ears) with relief of hearing loss or discomfort.</LI>
<LI>Proportion of people requiring further intervention to improve symptoms.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-12 12:58:44 +0000" MODIFIED_BY="Jenny Bellorini">
<P>We conducted systematic searches for randomised controlled trials. There were no language, publication year or publication status restrictions. The date of the last search was 23 April 2008. We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I> 2008, issue 2); MEDLINE; EMBASE; CINAHL; BNID; LILACS; KoreaMed; IndMed; PakMediNet; Zetoc; Cambridge Scientific Abstracts; ISI Proceedings; UKCRN; UKCTG; the National Research Register (Archive); and <I>m</I>RCT (Current Controlled Trials).</P>
<P>We modelled subject strategies for databases on the search strategy designed for CENTRAL. Where appropriate, we combined subject strategies with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in <I>The Cochrane Handbook</I> <I>for Systematic Reviews of Interventions</I> Appendix 5c (<LINK REF="REF-Handbook-2006" TYPE="REFERENCE">Handbook 2006</LINK>)). The search terms used to search CENTRAL, MEDLINE and EMBASE are set out in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>
</P>
<P>One author then scanned the initial search results to identify trials which loosely met the inclusion criteria. We scanned reference lists from identified publications and contacted authors as necessary. We undertook a forward search on the authors of the identified trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-12 12:57:52 +0000" MODIFIED_BY="Jenny Bellorini">
<STUDY_SELECTION MODIFIED="2008-05-13 11:25:48 +0100" MODIFIED_BY="[Empty name]">
<P>The two authors reviewed the full text articles of all the retrieved trials of possible relevance and applied the inclusion criteria independently. We resolved any differences in opinion about which studies to include in the review by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-12 12:57:52 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Data from the studies were extracted by one author and rechecked by the other author. We performed data extraction using standardised forms so as to allow an intention-to-treat analysis. Where data were missing, one author wrote to the authors of the studies requesting further information.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-05-14 09:08:18 +0100" MODIFIED_BY="Jenny Bellorini">
<P>The two authors independently assessed the quality of all included trials, and resolved any differences in opinion by discussion. We used a modification of the method used by <LINK REF="REF-Chalmers-1990" TYPE="REFERENCE">Chalmers 1990</LINK>. We assessed the selected studies for the following characteristics:</P>
<OL>
<LI>the adequacy of the randomisation process;</LI>
<LI>the potential for selection bias after allocation to study group, i.e. losses to follow up and whether analysis was by intention-to-treat;</LI>
<LI>whether there was blinding of outcome assessors to the participants' study group;</LI>
<LI>quality of outcome assessment.</LI>
</OL>
<P>Studies were graded A, B or C for their overall methodological quality:</P>
<P>A: minimisation of bias in all four categories above, i.e. adequate randomisation; few losses to follow up and intention-to-treat analysis; blinding of outcome assessors; high quality outcome assessment.<BR/>B: each of the criteria in A partially met.<BR/>C: one or more of the criteria in A not met.</P>
<P>Although we intended to use study quality for sensitivity analysis, this was not appropriate in the circumstances.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-05-13 11:22:10 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible we analysed data to give a summary measure of effect, although most data were not comparable or of sufficient quality.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-12 12:57:24 +0000" MODIFIED_BY="Jenny Bellorini">
<STUDY_DESCRIPTION MODIFIED="2008-11-12 12:57:24 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Of the 86 abstracts retrieved from our original searches in March 2003, 60 were immediately considered unsuitable for inclusion and 26 controlled trials were considered to be possibly relevant. Two of the papers were duplicate studies (<LINK REF="REF-Anon-1971" TYPE="REFERENCE">Anon 1971</LINK>; <LINK REF="REF-Masterson-2000" TYPE="REFERENCE">Masterson 2000</LINK>) and two were in vitro trials (<LINK REF="REF-Driver-1999" TYPE="REFERENCE">Driver 1999</LINK>; <LINK REF="REF-Robinson-1989" TYPE="REFERENCE">Robinson 1989</LINK>). Of the remaining 22 trials, five did not satisfy the inclusion criteria (<LINK REF="STD-Baker-1969" TYPE="STUDY">Baker 1969</LINK>; <LINK REF="STD-Hewitt-1970" TYPE="STUDY">Hewitt 1970</LINK>; <LINK REF="STD-Hinchcliffe-1955" TYPE="STUDY">Hinchcliffe 1955</LINK>
; 
<LINK REF="STD-Proudfoot-1968" TYPE="STUDY">Proudfoot 1968</LINK>; <LINK REF="STD-Spiro-1997" TYPE="STUDY">Spiro 1997</LINK>) and nine were excluded because no data addressing the primary outcome measure was either presented or extractable from the data provided (<LINK REF="STD-Amjad-1975" TYPE="STUDY">Amjad 1975</LINK>; <LINK REF="STD-Burgess-1966" TYPE="STUDY">Burgess 1966</LINK>; <LINK REF="STD-Carr-2001" TYPE="STUDY">Carr 2001</LINK>; <LINK REF="STD-de-Saintonge-1973" TYPE="STUDY">de Saintonge 1973</LINK> <LINK REF="STD-Dummer-1992" TYPE="STUDY">Dummer 1992</LINK>; <LINK REF="STD-Eekhof-2001" TYPE="STUDY">Eekhof 2001</LINK>; <LINK REF="STD-Fraser-1970" TYPE="STUDY">Fraser 1970</LINK>; <LINK REF="STD-GPRG-1965" TYPE="STUDY">GPRG 1965</LINK>; <LINK REF="STD-GPRG-1967" TYPE="STUDY">GPRG 1967</LINK>), leaving eight included studies.</P>
<P>Of the additional 92 abstracts retrieved from our update search in April 2008, 89 were immediately considered unsuitable for inclusion. Three studies were considered possibly relevant, but on further examination two studies were excluded; <LINK REF="STD-Pavlidis-2005" TYPE="STUDY">Pavlidis 2005</LINK>, a study examining the pre-instillation of water to facilitate syringing, because no data addressing our primary outcome measure was presented, and <LINK REF="STD-Roland-2004" TYPE="STUDY">Roland 2004</LINK> because it measured the combined effect of cerumenolytics and irrigation. One new study from the update search was therefore included (<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>).</P>
<P>With the addition of one more included study to the original eight trials, we found nine trials that satisfied our inclusion criteria (<LINK REF="STD-Fahmy-1982a" TYPE="STUDY">Fahmy 1982a</LINK>; <LINK REF="STD-Fahmy-1982b" TYPE="STUDY">Fahmy 1982b</LINK>; <LINK REF="STD-Fahmy-1982c" TYPE="STUDY">Fahmy 1982c</LINK>; <LINK REF="STD-Jaffe-1978" TYPE="STUDY">Jaffe 1978</LINK>; <LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>; <LINK REF="STD-Lyndon-1992" TYPE="STUDY">Lyndon 1992</LINK>; <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>; <LINK REF="STD-Singer-2000" TYPE="STUDY">Singer 2000</LINK>; <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>).The methods, participants, interventions and outcomes of the included studies are listed in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. A wide range of cerumenolytics were administered in these studies, and the duration of treatment varied between one and 14 days. It was not always possible to determine accurately the dose of cerumenolytic given.</P>
<P>Studies are divided into three types for ease of comparison (with several studies falling into more than one category): </P>
<P>A: Comparison of active treatments versus no treatment; <BR/>B: Comparison of alternative active treatments versus water or saline 'placebo'; <BR/>C: Head-to-head comparisons of alternative active treatments. </P>
<P>The studies and interventions are tabulated in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">A: Comparison of active treatment versus no treatment</HEADING>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>
<BR/>This double-blind, randomised controlled trial sought to determine the feasibility of significantly reducing the number of people who require ear syringing by the use of solvents, and to compare the efficacy of oil- and water-based solvents with the natural expulsion of ear wax. One hundred and thirteen geriatric inpatients with one or both ears impacted with wax were recruited; of these, 13 went home and three died during the five-day trial period (data were excluded), with 97 people (155 ears) completing the study. These participants had been randomly divided into four groups in order to receive: no treatment - 24 people (38 ears); sterile water - 24 people (38 ears) were treated with four drops of sterile water twice daily for five days; sodium bicarbonate - 25 people (39 ears) were treated with four drops of sodium bicarbonate ear drops (NaHCO3 5 g [sic], glycerol and purified water) twice daily for five days; and chlorbutanol (Cerumol®) - 24 people (40 ears) were treated with four drops of chlorbutanol (Cerumol® - ingredients: chlorbutanol 5%, turpentine oil 10%, paradichlorobenzene 2%, arachis oil 57.3%) twice daily for five days. Post-treatment, all participating ears were re-examined for the degree of impacted wax remaining and were classified as either still impacted, moderately clear, or completely clear. The desired primary outcome measure for the current review was the proportion of participants with sufficient clearance of the external canal, as determined by otoscopy, to make further mechanical clearance unnecessary. For purposes of analysis in this review, those ears 'moderately clear' or 'completely clear' were deemed to fulfil this criterion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">B: Comparison of alternative active treatments versus water or saline 'placebo'</HEADING>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>
<BR/>This study, described above, reported comparison of two alternative active treatments: sodium bicarbonate ear drops and chlorbutanol (Cerumol®), with sterile water.</P>
<P>
<LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>
</P>
<P>This prospective, double-blind, randomised controlled trial compared docusate sodium (Colace®), triethanolamine polypeptide (Cerumenex®) and normal saline as cerumenolytics with and without normal saline irrigation, and sought to evaluate the role of irrigation in cerumen removal. A convenience sample of 48 children (24 males and 24 females, mean age 4.6 years) with cerumen rated as either completely or partially occluding the tympanic membrane were recruited from a university paediatric emergency department (from 2/2001 to 11/2001) and randomly divided into three groups (of 17, 15 and 16 children) to receive 1 ml of either triethanolamine polypeptide (Cerumenex®), docusate sodium (Colace®) or a control of normal saline respectively. If, after 15 minutes, the tympanic membrane was still occluded, irrigation with 50 ml of normal saline was performed and, if needed, repeated once. The outcome measure was the amount of tympanic membrane visualised, with participants re-scored as having either complete occlusion of the tympanic membrane, partial occlusion, or as being clear. Any adverse effects were recorded.</P>
<P>
<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>
</P>
<P>Like Meehan 2002, this prospective, randomised, double-blind study compared the cerumenolytic activity of three different solutions: docusate sodium, triethanolamine polypeptide and normal saline in 92 children aged between six months and five years with complete or partial cerumen obstruction of the tympanic membrane. Application of the drops for 15 minutes was followed, if required, by a maximum of two attempts of syringing with 50 ml of tepid tap water. The wax was identified as soft, mixed and hard and the obstruction as partial or complete depending on whether a part of the eardrum was visible on otoscopy. Thirty-four of the 92 children enrolled received docusate sodium, 30 received triethanolamine polypeptide and 28 received saline. The main outcome of the study was the proportion of tympanic membranes that were completely visualised after treatment alone or after treatment plus irrigation if necessary. The sample size of 90 was estimated to achieve 80% power to detect a 40 percentage-point difference between the treatment groups, based on the results of a previous study (<LINK REF="STD-Singer-2000" TYPE="STUDY">Singer 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">C: Head-to-head comparisons of alternative active treatments</HEADING>
<P>
<LINK REF="STD-Jaffe-1978" TYPE="STUDY">Jaffe 1978</LINK>
<BR/>This randomised, double-blind clinical trial compared the cerumenolytic effectiveness of chlorbutanol (Cerumol® - turpentine oil 10%, chlorbutanol 5%, paradichlorobenzene 2%, arachis oil 57.3%) with almond oil + arachis oil + rectified camphor oil (Otocerol®). One hundred and six people (children and adults, 0 to 89 years) with hard or impacted wax presenting at 15 general practices were recruited and randomised into two equal groups. Their degree of impaction was assessed at baseline as either mild (soft wax, which could be syringed at once if necessary), moderate (small plug of hard wax for which a cerumenolytic would usually be used before syringing), or severe (large plug of hard wax for which a cerumenolytic would be essential). The chlorbutanol group (53 people) was instructed to instil five drops daily at night into the ears for three days, and the almond oil group (53 people) to instil four drops daily at night for three days (both treatments as per manufacturers' instructions). All participants then returned for examination and syringing if necessary. Outcomes measured were the degree of impaction of wax after treatment, the necessity for syringing, and the ease of syringing where required. Neither the age, nor sex, nor degree of impaction differences between the groups were considered statistically significant by the authors. Side effects were noted.</P>
<P>
<LINK REF="STD-Fahmy-1982a" TYPE="STUDY">Fahmy 1982a</LINK>
<BR/>This was a quasi-randomised, double-blind controlled trial examining the effectiveness of hydrogen peroxide solution (Exterol® - 5% urea hydrogen peroxide in anhydrous glycerol) for the treatment of persistent ear wax. Forty people (80 ears) with hard or impacted wax were recruited from a hospital ENT department and divided equally between test (40 ears receiving hydrogen peroxide solution (Exterol®)) and 40 ears receiving glycerol as the control. All participants were assessed for degree of wax occlusion and consistency of wax before treatment, and were then instructed to instil 5 to 10 drops into the affected ear twice daily for seven days, and to return for re-examination. The outcome measure was the ease of wax dispersal after treatment (with or without syringing).</P>
<P>
<LINK REF="STD-Fahmy-1982b" TYPE="STUDY">Fahmy 1982b</LINK>
<BR/>Fifty people (100 ears) with impacted wax were recruited from a hospital ENT department and assessed for the degree of wax occlusion and consistency of wax before treatment. The participants were then randomly divided into two groups by alternation: one group (25 people) was treated with hydrogen peroxide solution (Exterol®) and the other group (25 people) with chlorbutanol (Cerumol®). The outcome measure was the ease of wax dispersal after treatment (with or without syringing).</P>
<P>
<LINK REF="STD-Fahmy-1982c" TYPE="STUDY">Fahmy 1982c</LINK>
<BR/>A total of 160 people (286 ears) were recruited from five UK general practices and assessed for the degree of wax occlusion and consistency of wax before treatment. The participants were then randomly divided into two groups: the first group (157 ears) was treated with hydrogen peroxide solution (Exterol®) and the other group (129 ears) was treated with chlorbutanol (Cerumol®). The outcome measure was the ease of wax dispersal after treatment (with or without syringing).</P>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>
<BR/>This study, described above, reported a comparison of two alternative active treatments: sodium bicarbonate ear drops (sodium bicarbonate + glycerol + water) and chlorbutanol (Cerumol®).</P>
<P>
<LINK REF="STD-Lyndon-1992" TYPE="STUDY">Lyndon 1992</LINK>
<BR/>Thirty-six people (19 males, mean age 52) presenting to a general practice with impacted wax in one or both ears were recruited to an open, randomised trial comparing the effectiveness of choline salicylate (Audax®) ear drops with a solution containing almond oil + arachis oil + camphor oil (Earex®). Pre-treatment examination rated the degree of wax impaction in all participants as either mild (could be syringed at once if necessary), moderate (small plug of hard wax), or severe (large plug of hard wax). The participants were then randomly divided into two groups, one (19 people, 38 ears) receiving choline salicylate solution and the other (17 people, 34 ears) receiving almond oil solution. Both groups were instructed to instil the agent twice daily for five days and then return for re-examination and one standardised syringing procedure if required. Outcomes assessed after treatment were degree of impaction and need for syringing (rated as none - syringing not required, mild, moderate, or severe), ease of syringing if required (rated as easy, difficult, or impossible), adverse effects (degree of irritation or discomfort), and global impression of efficiency of the drops by both investigator and participants (rated as completely effective, very effective, fairly effective, or not effective).</P>
<P>
<LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>
<BR/>This study, described above, reported a comparison of two alternative active treatments: docusate sodium (Colace®) and triethanolamine (Cerumenex®) in children.</P>
<P>
<LINK REF="STD-Singer-2000" TYPE="STUDY">Singer 2000</LINK>
<BR/>A prospective, randomised, double-blind controlled clinical trial comparing the cerumenolytic effects of docusate sodium (Colace®) with triethanolamine polypeptide (Cerumenex®) in people with impacted cerumen. Fifty adults and children (age range 1 to 81 years, 26% children) presenting to a university-based emergency department with a medical condition requiring tympanic visualisation and with partially or totally obscured tympanic membranes were recruited. Participants were randomly divided into two groups and examined, with visualisation of the tympanic membrane classified as either partially or completely obscured. Groups were similar in age (mean = 40 years), sex (35% female), and proportion of completely obscured tympanic membranes at presentation (78%). Both groups received a single intra-aural installation in one ear only of 1 ml of either docusate sodium (27 participants) or triethanolamine polypeptide (23 participants) in liquid form. If not completely cleared within 15 minutes, the external ear canal was irrigated up to three times with 50 ml (100 ml on third syringing) of normal saline solution followed each time by re-examination. Adverse effects such as pain, vertigo, nausea or hearing loss were noted. The main outcome measure was the proportion of ears in which the tympanic membrane could be totally visualised after treatment instillation with or without irrigation. The authors stated that the study had 80% power to detect a 40% difference between groups in the proportion of totally visualised tympanic membranes.</P>
<P>
<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>
<BR/>This study, described above, reported a comparison of two alternative active treatments: docusate sodium versus triethanolamine polypeptide in children.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-12 12:55:15 +0000" MODIFIED_BY="Jenny Bellorini">
<P>All randomised controlled trials were subjected to a critical review of their methodology by the two authors and were graded for their overall methodological quality according to the stated criteria.</P>
<P>Methodological quality varied between studies, but was generally low with two studies scoring an A grade (<LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>
; 
<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>), two scoring B (<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>; <LINK REF="STD-Singer-2000" TYPE="STUDY">Singer 2000</LINK>) and the remaining five studies scoring C (<LINK REF="STD-Fahmy-1982a" TYPE="STUDY">Fahmy 1982a</LINK>; <LINK REF="STD-Fahmy-1982b" TYPE="STUDY">Fahmy 1982b</LINK>; <LINK REF="STD-Fahmy-1982c" TYPE="STUDY">Fahmy 1982c</LINK>; <LINK REF="STD-Jaffe-1978" TYPE="STUDY">Jaffe 1978</LINK>; <LINK REF="STD-Lyndon-1992" TYPE="STUDY">Lyndon 1992</LINK>).</P>
<P>Although all were randomised trial designs, only four described adequate randomisation and concealment procedures (<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>; <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>; <LINK REF="STD-Singer-2000" TYPE="STUDY">Singer 2000</LINK>; <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies graded A</HEADING>
<P>In <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>, although no details of the randomisation method were given in the published trial, when contacted the main author recalled that a hospital pharmacist randomised the allocation by patient ID number using the Quattro-Pro randomisation programme with a Permuted Block Method, and that the test agents were concealed at the pharmacy in coloured, number-coded syringes (grade A).</P>
<P>In <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>, the allocation was performed by the hospital pharmacist using consecutively numbered envelopes, with the assignments generated randomly by a computerised random-number programme. There were four investigators, but prior to study commencement each investigator examined the same 26 ears and evaluated the degree of obstruction of the tympanic membrane in order to identify inter-observer variability. A k value of 0.72 was obtained, indicating (according to the study authors) a good agreement between the observers. Although this was a convenience sample of patients (and so a selection bias cannot be excluded), the study was graded A.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies graded B</HEADING>
<P>Despite providing no details in the published trial, when contacted the author of <LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK> recalled that a hospital pharmacist randomised and concealed the allocation by coding, and that the treatment was administered by nurses and assessed by the investigator with the code remaining unbroken until the trial was complete. However, the data for the 16 participants who failed to complete the study were excluded and an intention-to-treat analysis was not performed by the authors.</P>
<P>In <LINK REF="STD-Singer-2000" TYPE="STUDY">Singer 2000</LINK> the allocation was concealed by the hospital pharmacy in a series of opaque, consecutively numbered, 2 ml syringes, and assignments were generated by a computerised random numbers programme. However, the two solvents were visibly different in colour, which may have introduced an observer/outcome assessor bias. Furthermore, the study was a convenience sample, so a selection bias cannot be excluded whereby people with particularly hard and impacted cerumen may not have been included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies graded C</HEADING>
<P>Of the remaining five trials, allocation concealment was either not described or not attempted in any of them. Two of these failed to describe the randomisation method (<LINK REF="STD-Jaffe-1978" TYPE="STUDY">Jaffe 1978</LINK>; <LINK REF="STD-Lyndon-1992" TYPE="STUDY">Lyndon 1992</LINK>), while the remaining three used an inadequate method, i.e. alternate preparations given out on a sequential basis (<LINK REF="STD-Fahmy-1982a" TYPE="STUDY">Fahmy 1982a</LINK>; <LINK REF="STD-Fahmy-1982b" TYPE="STUDY">Fahmy 1982b</LINK>; <LINK REF="STD-Fahmy-1982c" TYPE="STUDY">Fahmy 1982c</LINK>).</P>
<P>Several attempts were made to contact all the authors in order to obtain further data, and two responses were received (<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>; <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>).</P>
<P>Six of the nine studies were double-blind, and three were unblinded (<LINK REF="STD-Fahmy-1982b" TYPE="STUDY">Fahmy 1982b</LINK>; <LINK REF="STD-Fahmy-1982c" TYPE="STUDY">Fahmy 1982c</LINK>; <LINK REF="STD-Lyndon-1992" TYPE="STUDY">Lyndon 1992</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-12 12:54:45 +0000" MODIFIED_BY="Jenny Bellorini">
<P>There was a lack of standardisation of outcome assessment across the nine included trials.</P>
<SUBSECTION>
<HEADING LEVEL="3">A: Comparison of active treatment versus no treatment</HEADING>
<P>Only one study compared the use of active treatments with no treatment (<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>In this study, neither sterile water nor sodium bicarbonate + glycerol + water were found to be significantly better than no treatment for preventing the need for syringing (respectively: P = 0.06, P = 0.19). However, in the comparison of chlorbutanol (Cerumol®) versus no intervention, chlorbutanol proved to be significantly better than no treatment (P = 0.01). When the results of all of the active treatments were combined and compared with the no treatment group, the proportions requiring no further clearance were 62/117 and 12/38 respectively (OR 2.44, 95% CI 1.13 to 5.30).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>No data were available from this study on the ease of mechanical removal following treatment, the proportion of participants with relief of hearing loss or discomfort, or the proportion requiring further intervention to improve symptoms. Data were available, however, on the number of ears that were completely clear versus the number moderately clear post-treatment, with all three treatments proving to be significantly better than no treatment (sterile water (P = 0.04), sodium bicarbonate + glycerol + water (P = 0.05), chlorbutanol (P = 0.03)). However, neither sodium bicarbonate + glycerol + water nor chlorbutanol performed significantly better than sterile water or each other.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">B: Comparison of alternative active treatments versus water or saline 'placebo'</HEADING>
<P>Three studies compared alternative active treatments with a water or saline placebo. In Keane's study of adults, all of whom had impacted wax at the start of the study, the drops were used for five days before the ears were re-assessed (<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>), while in both <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK> and <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK> children with either complete or partial occlusion of the ear canal received a single instillation of ear drops followed by syringing of the ear after 15 minutes, if required.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK> compared both sodium bicarbonate + glycerol + water and chlorbutanol (Cerumol®) with a water placebo. Neither was found to be significantly better than water at preventing the need for syringing (respectively: P = 0.57, P = 0.51).</P>
<P>Data from <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK> allow comparison of docusate sodium (Colace®) with saline placebo, and triethanolamine polypeptide (Cerumenex®) with a saline placebo. After agent alone, complete visualisation of the tympanic membrane was achieved in two (13%) of the 15 patients receiving docusate sodium compared with two (12.5%) of the 16 patients receiving saline placebo (P = 0.94), and in 7 (41%) of 17 receiving triethanolamine polypeptide compared with two (12.5%) of 16 receiving saline placebo (P = 0.08), indicating that neither active agent docusate sodium nor triethanolamine polypeptide was found to be significantly better than saline. It should be recalled that not all children had completely occluded ears to start with, possibly introducing bias due to baseline differences if the proportion with only partial obstruction was different in the two groups.</P>
<P>
<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK> also compared both docusate sodium and triethanolamine polypeptide with a saline placebo in children. Similar to Meehan's study, ears were not syringed if the tympanic membrane was completely visible after the drops, and again not all the children started with completely occluded ears. This possibly introduced a bias due to baseline differences, though some of the confounding factors were analysed. After agent alone, complete visualisation of the tympanic membrane was achieved in four (12%) of the 34 docusate sodium patients, four (13%) of the 30 triethanolamine polypeptide patients and one (4%) of the 28 saline controls (P = 0.26, P = 0.22).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Meta-analysis</HEADING>
<P>As both <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK> and <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK> compared the topical cerumenolytics with saline placebo in children and were of high methodological quality (both graded A), their results were combined in a meta-analysis. Of the combined results, one was significant. In the comparison of triethanolamine polypeptide (Cerumenex®) with saline, the former proved to be significantly more effective than saline in clearing impacted cerumen sufficiently so that the syringing was unnecessary with an odds ratio (OR) of 3.77 (95% CI 1.18 to 12.04) (triethanolamine polypeptide (Cerumenex®): <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; docusate sodium (Colace®): <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>No data were available from Keane's study on the ease of mechanical removal following treatment, the proportion of participants with relief of hearing loss or discomfort, or the proportion requiring further intervention to improve symptoms. Data were available on the number of ears that were completely clear versus the number moderately clear: there was no significant difference between the proportion of ears completely or moderately clear when either sodium bicarbonate + glycerol + water or Cerumol® was compared with a water placebo.</P>
<P>No data were available from Meehan's study on the ease of mechanical removal following treatment, the proportion of participants with relief of hearing loss or discomfort, or the proportion requiring further intervention to improve symptoms. Since the proportion of ears which at the start were completely occluded, as compared to partially occluded, varied between groups, meaningful conclusions cannot be drawn (only those ears which were completely clear were not syringed after the drops had been used).</P>
<P>Both <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK> and <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK> report data on the effectiveness of syringing in producing 'clear' visualisation of the tympanic membrane in those participants who continued to have complete or partial obstruction after using drops. In <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK> the number of participants whose ears were cleared at the first syringing attempt after the use of triethanolamine polypeptide (Cerumenex®), docusate sodium (Colace®) or a saline placebo were one, one and four respectively. To calculate the proportion in each group the denominator ought to be the number of participants whose ears were syringed, not the number originally in each group, and this should be equal to the number originally in each group less those whose ears were completely cleared by drops alone. The numbers reported in the paper differ however, suggesting that some participants did not go on and have their ears syringed <I>even though</I> their ears were not clear as a result of the use of drops alone. To try and adhere to 'intention-to-treat' principles, we have chosen to use as the denominator the number in each group whose ears were not cleared by drops alone, that is 10, 12 and 14 respectively, giving clearance rates of syringing of 10%, 8.3% and 29% respectively; there is no significant difference between the active agents and placebo.</P>
<P>In <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK> after the first irrigation, complete visualisation was possible in nine of the remaining 30 unclear ears in the docusate sodium group, eight of the remaining 26 in the triethanolamine group and 11 of the remaining 27 in the saline control group. The respective proportions were 30%, 31% and 41%. None of these results indicate that either sodium docusate or triethanolaminepolypeptide was significantly better than saline. One minor adverse event was recorded (a patient with a small amount of ear canal bleeding after irrigation), but no further treatment was required and the patient was able to complete the study.</P>
<P>Other secondary outcomes specific to the study, such as difference in the success rates between sites, investigators and the type of wax, were not found to be significant by the study authors although the success rate was higher for the removal of soft wax (68%) than for mixed (50%) or hard wax (43%).</P>
<P>The results from both <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK> and <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK> were combined in a meta-analysis (triethanolamine polypeptide (Cerumenex®): <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; docusate sodium (Colace®): <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Neither agent was found to be better than saline.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">C: Head-to-head comparisons of alternative active treatments</HEADING>
<P>Data from several other studies allow head-to-head comparisons between alternative active treatments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1. Chlorbutanol (Cerumol®) versus almond oil + arachis oil + rectified camphor oil (Otocerol®)</HEADING>
<P>This comparison was studied by <LINK REF="STD-Jaffe-1978" TYPE="STUDY">Jaffe 1978</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>Almond oil + arachis oil + rectified camphor oil (Otocerol®) was significantly better than chlorbutanol (Cerumol®) (P = 0.05) at preventing the need for syringing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>Jaffe assessed whether ear syringing was 'easy' or 'not easy'. Of those that needed syringing, there was no significant difference (P = 0.63) between the two treatments.</P>
<P>No data were available from this study on the proportion of participants with relief of hearing loss or discomfort.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Hydrogen peroxide (Exterol®) versus Glycerol</HEADING>
<P>This comparison was studied by Fahmy (<LINK REF="STD-Fahmy-1982a" TYPE="STUDY">Fahmy 1982a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>Hydrogen peroxide (Exterol®) was significantly better than glycerol (P = 0.01) at preventing the need for syringing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>Fahmy assessed whether ears syringed 'easily' or 'with difficulty'. Of those that needed syringing, a significantly greater proportion syringed easily with hydrogen peroxide (P = 0.001). No data were available from these studies on the proportion of participants with relief of hearing loss or discomfort.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Hydrogen peroxide (Exterol®) versus chlorbutanol (Cerumol®)</HEADING>
<P>Two further studies by Fahmy compared hydrogen peroxide (Exterol®) with chlorbutanol (Cerumol®) (<LINK REF="STD-Fahmy-1982b" TYPE="STUDY">Fahmy 1982b</LINK>; <LINK REF="STD-Fahmy-1982c" TYPE="STUDY">Fahmy 1982c</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>Both studies demonstrated hydrogen peroxide (Exterol®) to be significantly better than chlorbutanol (Cerumol®) (<LINK REF="STD-Fahmy-1982b" TYPE="STUDY">Fahmy 1982b</LINK>: P = &lt; 0.01), (<LINK REF="STD-Fahmy-1982c" TYPE="STUDY">Fahmy 1982c</LINK>: P = &lt; 0.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>As in the previous study, in both these trials Fahmy assessed whether ears syringed 'easily' or 'with difficulty'. Of those that needed syringing, a significantly greater proportion of participants in both trials syringed easily with hydrogen peroxide (Exterol®) than with chlorbutanol (Cerumol®): <LINK REF="STD-Fahmy-1982b" TYPE="STUDY">Fahmy 1982b</LINK>: P &lt; 0.0001; <LINK REF="STD-Fahmy-1982c" TYPE="STUDY">Fahmy 1982c</LINK>: P = 0.0001.</P>
<P>No data were available from these studies on the proportion of participants with relief of hearing loss or discomfort.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Choline salicylate (Audax®) versus almond oil + arachis oil + camphor oil (Earex®)</HEADING>
<P>This comparison was studied by <LINK REF="STD-Lyndon-1992" TYPE="STUDY">Lyndon 1992</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>No significant difference was demonstrated between choline salicylate (Audax®) and almond oil + arachis oil + camphor oil (Earex®) in terms of the proportion needing syringing (P = 0.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>Lyndon assessed whether ear syringing was 'easy', 'difficult' or 'impossible'. There were no cases in this last category. Of those that needed syringing, choline salicylate (Audax®) was significantly better than almond oil + arachis oil + camphor oil (Earex®) (P = 0.0009).</P>
<P>No data were available from this study on the proportion of participants with relief of hearing loss or discomfort.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Sodium bicarbonate + glycerol + water versus chlorbutanol (Cerumol®)</HEADING>
<P>This comparison was made in <LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>Keane's study fails to demonstrate any significant difference between sodium bicarbonate + glycerol + water and chlorbutanol (Cerumol®) in preventing the need for syringing (P = 0.22).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>No data were available from this study on the ease of mechanical removal following treatment, the proportion of participants with relief of hearing loss or discomfort, or the proportion requiring further intervention to improve symptoms.</P>
<P>Data were available on the number of ears that were completely clear versus the number moderately clear. There was no significant difference between the proportion of ears completely or moderately clear when sodium bicarbonate + glycerol + water was compared with chlorbutanol (Cerumol®) (P = 0.65).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Triethanolamine polypeptide (Cerumenex®) versus docusate sodium (Colace®)</HEADING>
<P>This comparison was examined in <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>, <LINK REF="STD-Singer-2000" TYPE="STUDY">Singer 2000</LINK> and <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>. The specific features of Meehan's and Whatley's studies have been outlined above. Singer's study was undertaken in a similar setting, albeit including adults as well as children. As in <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK> and <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>, a single dose of treatment was given 15 minutes before assessment of the need for syringing.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measure</HEADING>
<P>In Singer 2000, in both adults and children combined, no significant difference was found (P = 0.33) between docusate sodium (Colace®) and triethanolamine polypeptide (Cerumenex®) in preventing the need for syringing after a single instillation of ear drops.</P>
<P>In <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK> however (children only) again the difference was not significant (P = 0.09). In 
<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK> (children only), neither preparation performed well: the number of ears clear after application of the active agent alone were docusate sodium, four out of 34 participants (12%), compared with triethanolamine polypeptide, four out of 30 participants (13%), from which the study authors concluded that neither docusate sodium nor triethanolamine polypeptide significantly improved complete visualisation of the tympanic membrane (P = 0.85). When the data from these two A-grade paediatric studies were combined in a meta-analysis there was still no significant difference between treatments (P = 0.29) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>Some data on the ease (i.e. number of syringing attempts necessary) and extent (clearance rates) of wax removal can be extracted from these three studies. The data from <LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK> and <LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK> have been reported above together with some important comments about the denominator used in calculating the proportion of participants whose ears were cleared by syringing after the use of drops. The results from the two studies were combined in a meta-analysis. No difference was found between the two agents (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
<P>In <LINK REF="STD-Singer-2000" TYPE="STUDY">Singer 2000</LINK>, docusate sodium again performed better than triethanolamine polypeptide; after the first irrigation the ears of 15 of the 27 patients receiving docusate sodium were cleared compared with the ears of four of the 23 patients receiving triethanolamine polypeptide, a statistically significant difference (P = 0.008), and after the second irrigation the difference was also significant in favour of docusate sodium (P = 0.001).</P>
<P>Within Singer's small paediatric (&lt; five years) population, although no data were given regarding prevention of the need for syringing, paediatric data were presented separately for irrigation post-treatment, in which docusate sodium (Colace®) appeared to perform better than triethanolamine polypeptide (Cerumenex®), although there was no statistically significant difference between the two treatments (P = 0.32). This data could not be combined within the meta-analysis as data was not given post-first irrigation.</P>
<P>No data were presented in any of these studies on the proportion of participants with relief of hearing loss or discomfort.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-14 09:18:05 +0100" MODIFIED_BY="Jenny Bellorini">
<P>All the included studies are in general of modest quality, and contain relatively small numbers of subjects. We took a pragmatic approach by choosing the need for syringing as a primary outcome measure, and found nine trials that addressed this issue. There was little information, however, within the included studies on the ease of syringing post-treatment: had this been the primary outcome measure more studies may have been eligible for inclusion, but perusal of the excluded studies suggests that the ways in which this outcome was measured varied considerably, and combining results from studies would again have proved difficult.</P>
<P>Within individual studies of good methodological quality (i.e. either grade A or B) addressing our primary outcome measure (prevention of the need for syringing), none of the comparisons showed any difference between active treatments nor between any active treatment and sterile water or saline. However, the one study which addresses our primary outcome measure and compares active treatments with no intervention suggests that using drops to remove wax may be better than nothing (<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>). That is, although impacted or obstructing wax will sometimes extrude on its own, drops of any sort may enhance the process. However, it should be emphasised that this statement is based on a single trial of moderate methodological quality and with a wide confidence interval. Proprietary wax-removing agents have not been shown to be superior to saline or water.</P>
<P>Heterogeneity between trials meant that only limited meta-analysis could be performed, and where results from the two trials of high methodological quality (<LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>; 
<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>, both grade A) addressing our primary outcome measure could be combined, there was only one significant difference shown - that triethanolamine polypeptide ear drops, instilled into the ears of small children for 15 minutes, proved to be better than saline at preventing the need for syringing. Whilst the point estimate of the odds ratio - about 4 - might seem favourable, the wide confidence interval (1.2 to 12) indicates that the true effect size may be very different. Meta-analysis of data addressing one of our secondary outcomes - clearance of wax post-treatment plus first syringing attempt - showed no difference between treatments.</P>
<P>There was no evidence presented in these studies about any harmful side effects of the agents studied. Perhaps none occurred. However, it is said, in standard texts, that some patients develop sensitivities to the constituents of some drops. Equally, it has been observed that using drops can, at least temporarily, lead to increased deafness, and if the drops are too cold when they are instilled, dizziness can result from a caloric effect on the inner ear. Syringing can produce damage to the delicate skin of the ear canal and, in some cases, perforation of the tympanic membrane. Infection may supercede in either circumstance. As a result, there is in the United Kingdom a tendency to avoid syringing and to use mechanical methods of wax removal employing suction or manipulation under direct vision.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-12 12:52:20 +0000" MODIFIED_BY="Jenny Bellorini">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-12 12:52:20 +0000" MODIFIED_BY="Jenny Bellorini">
<P>There are no good data on which to base recommendations to use one particular cerumenolytic in preference to any other. Saline or water seems to be as effective as any proprietary agent and both have the virtue of being cheap and readily available. There is weak evidence that a short, 15-minute period of instillation of triethanolamine polypeptide ear drops, prior to syringing may be helpful.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further trials of high methodological quality, with suitable sample sizes, need to be undertaken to assess the relative merits of different cerumenolytics. In particular they should compare oil-based and water-based solvents with placebo. If ease of syringing is to be used routinely as an outcome measure, some standardised method of measuring this should be agreed upon. As other mechanical methods of wax removal (for example, micro-suction) become more common in some parts of the world, the effectiveness and risks of these methods should also be rigorously evaluated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST MODIFIED="2008-05-14 09:18:29 +0100" MODIFIED_BY="Jenny Bellorini">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-05-14 09:18:25 +0100" MODIFIED_BY="Jenny Bellorini">
<P>MARTIN BURTON: Lead author, design of review, study selection, quality assessment, analysis and interpretation of data, and writing of review.</P>
<P>CAROLYN DOREE: Searching for trials, study selection, data extraction, quality assessment, data analysis, and writing of review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-12 12:49:17 +0000" MODIFIED_BY="Jenny Bellorini">
<STUDIES MODIFIED="2008-05-14 09:40:45 +0100" MODIFIED_BY="Jenny Bellorini">
<INCLUDED_STUDIES MODIFIED="2008-05-14 09:38:23 +0100" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="PUB" ID="STD-Fahmy-1982a" MODIFIED="2008-05-14 09:37:22 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Fahmy 1982a" YEAR="1982">
<REFERENCE MODIFIED="2008-05-14 09:37:22 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fahmy S, Whitefield M</AU>
<TI>Multicentre clinical trial of Exterol® as a cerumenolytic</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1982</YR>
<VL>36</VL>
<NO>5</NO>
<PG>197-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fahmy-1982b" MODIFIED="2008-05-14 09:37:26 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Fahmy 1982b" YEAR="1982">
<REFERENCE MODIFIED="2008-05-14 09:37:26 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fahmy S, Whitefield M</AU>
<TI>Multicentre clinical trial of Exterol® as a cerumenolytic</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1982</YR>
<VL>36</VL>
<NO>5</NO>
<PG>197-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fahmy-1982c" MODIFIED="2008-05-14 09:37:29 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Fahmy 1982c" YEAR="1982">
<REFERENCE MODIFIED="2008-05-14 09:37:29 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fahmy S, Whitefield M</AU>
<TI>Multicentre clinical trial of Exterol® as a cerumenolytic</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1982</YR>
<VL>36</VL>
<NO>5</NO>
<PG>197-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaffe-1978" MODIFIED="2008-05-14 09:37:36 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Jaffe 1978" YEAR="1978">
<REFERENCE MODIFIED="2008-05-14 09:37:36 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaffe G, Grimshaw J</AU>
<TI>A multicentric clinical trial comparing Otocerol® with Cerumol® as cerumenolytics</TI>
<SO>Journal of International Medical Research</SO>
<YR>1978</YR>
<VL>6</VL>
<PG>241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Keane-1995" NAME="Keane 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keane EM, Wilson H, McGrane D, Coakley D, Walsh JB</AU>
<TI>Use of solvents to disperse ear wax</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1995</YR>
<VL>49</VL>
<NO>2</NO>
<PG>71-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Keane EM</AU>
<SO>Personal correspondence (email)</SO>
<YR>27 March 2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyndon-1992" MODIFIED="2008-05-14 09:37:44 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Lyndon 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-05-14 09:37:44 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyndon S, Roy P, Grillage MG, Miller AJ</AU>
<TI>A comparison of the efficacy of two ear drop preparations (Audax® and Earex®) in the softening and removal of impacted ear wax</TI>
<SO>Current Medical Research Opinions</SO>
<YR>1992</YR>
<VL>13</VL>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meehan-2002" NAME="Meehan 2002" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meehan P, Isenhour JL, Reeves R, Wrenn K</AU>
<TI>Ceruminolysis in the pediatric patient: a prospective, double-blinded, randomized controlled trial</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>5</NO>
<PG>521-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Meehan P</AU>
<SO>Personal correspondence (email)</SO>
<YR>18 April 2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singer-2000" MODIFIED="2008-05-14 09:37:56 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Singer 2000" YEAR="">
<REFERENCE MODIFIED="2008-05-14 09:37:56 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson A</AU>
<TI>Docusate sodium with irrigation was better than triethanolamine polypeptide with irrigation for dissolving earwax</TI>
<SO>Evidence-Based Nursing</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>2</NO>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Singer AJ, Sauris E, Viccellio AW</AU>
<TI>Ceruminolytic effects of docusate sodium: a randomized, controlled trial</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>3</NO>
<PG>228-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whatley-2003" MODIFIED="2008-05-14 09:38:23 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Whatley 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-05-14 09:38:23 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whatley VN, Dodds CL, Paul RI</AU>
<TI>Randomized clinical trial of docusate, triethanolamine polypeptide, and irrigation in cerumen removal in children</TI>
<SO>Archives of Paediatrics and Adolescent Medicine</SO>
<YR>2003</YR>
<VL>157</VL>
<NO>12</NO>
<PG>1177-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-05-14 09:40:25 +0100" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="PUB" ID="STD-Amjad-1975" NAME="Amjad 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amjad AH, Scheer AA</AU>
<TI>Clinical evaluation of cerumenolytic agents</TI>
<SO>Eye, Ear, Nose and Throat Monthly</SO>
<YR>1975</YR>
<VL>54</VL>
<PG>74-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-1969" NAME="Baker 1969" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker BS</AU>
<TI>A clinical trial of a ceruminolytic agent</TI>
<SO>Transactions of the Society for Occupational Medicine</SO>
<YR>1969</YR>
<VL>19</VL>
<PG>62-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgess-1966" MODIFIED="2008-05-14 09:38:42 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Burgess 1966" YEAR="1966">
<REFERENCE MODIFIED="2008-05-14 09:38:42 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgess EH</AU>
<TI>A wetting agent to facilitate ear syringing</TI>
<SO>The Practitioner</SO>
<YR>1966</YR>
<VL>197</VL>
<NO>182</NO>
<PG>811-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carr-2001" NAME="Carr 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carr MM, Smith RL</AU>
<TI>Ceruminolytic efficacy in adults versus children</TI>
<SO>Journal of Otolaryngology</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>3</NO>
<PG>154-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Saintonge-1973" NAME="de Saintonge 1973" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaput de Saintonge DM, Johnstone CI</AU>
<TI>A clinical comparison of triethanolamine polypeptide oleate-condensate ear drops with olive oil for the removal of impacted wax</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1973</YR>
<VL>27</VL>
<PG>454-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubow-1959" MODIFIED="2008-05-14 09:39:11 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Dubow 1959" YEAR="1959">
<REFERENCE MODIFIED="2008-05-14 09:39:11 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubow E</AU>
<TI>A simple method to assure proper pediatric ear examinations</TI>
<SO>Archives of Pediatrics</SO>
<YR>1959</YR>
<VL>76</VL>
<PG>360-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dummer-1992" NAME="Dummer 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dummer DS, Sutherland IA, Murray JA</AU>
<TI>A single-blind, randomized study to compare the efficacy of two ear drop preparations (Audax® and Cerumol®) in the softening of ear wax</TI>
<SO>Current Medical Research Opinions</SO>
<YR>1992</YR>
<VL>13</VL>
<PG>26-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eekhof-2001" NAME="Eekhof 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eekhof JA, de Bock GH, Le Cessie S, Springer MP</AU>
<TI>A quasi-randomised controlled trial of water as a quick softening agent of persistent earwax in general practice</TI>
<SO>British Journal of General Practice</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>469</NO>
<PG>635-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fraser-1970" NAME="Fraser 1970" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fraser, JG</AU>
<TI>The efficacy of wax solvents: in vitro studies and a clinical trial</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>1970</YR>
<VL>84</VL>
<PG>1055-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GPRG-1965" NAME="GPRG 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>General Practitioner Research Group</AU>
<TI>A wetting agent to facilitate ear syringing</TI>
<SO>The Practitioner</SO>
<YR>1965</YR>
<VL>195</VL>
<PG>810-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GPRG-1967" NAME="GPRG 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>General Practitioner Research Group</AU>
<TI>Wax softening with a new preparation</TI>
<SO>The Practitioner</SO>
<YR>1967</YR>
<VL>199</VL>
<PG>359-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hewitt-1970" NAME="Hewitt 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hewitt HR</AU>
<TI>Clinical evaluation of choline salicylate ear-drops</TI>
<SO>The Practitioner</SO>
<YR>1970</YR>
<VL>204</VL>
<PG>438-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hinchcliffe-1955" MODIFIED="2008-05-14 09:39:24 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Hinchcliffe 1955" YEAR="1955">
<REFERENCE MODIFIED="2008-05-14 09:39:24 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hinchcliffe R</AU>
<TI>Effect of current cerumenolytics</TI>
<SO>British Medical Journal</SO>
<YR>1955</YR>
<VL>2</VL>
<PG>722</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavlidis-2005" MODIFIED="2008-05-14 09:39:38 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Pavlidis 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-14 09:39:38 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavlidis C, Pickering JA</AU>
<TI>Water as a fast acting wax softening agent before ear syringing</TI>
<SO>Australian Family Physician</SO>
<YR>2005</YR>
<VL>34</VL>
<NO>4</NO>
<PG>303-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Proudfoot-1968" NAME="Proudfoot 1968" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Proudfoot J</AU>
<TI>Clinical trial of a ceruminolytic agent in general practice</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>February 1968</YR>
<VL>22</VL>
<NO>2</NO>
<PG>69-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roland-2004" MODIFIED="2008-05-14 09:40:08 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Roland 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-14 09:40:08 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roland PS, Eaton DA, Gross RD, Wall GM, Conroy PJ, Garadi R, et al</AU>
<TI>Randomized, placebo-controlled evaluation of Cerumenex and Murine earwax removal products</TI>
<SO>Archives of Otolaryngology - Head and Neck Surgery</SO>
<YR>2004</YR>
<VL>130</VL>
<NO>10</NO>
<PG>1175-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spiro-1997" MODIFIED="2008-05-14 09:40:25 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Spiro 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-05-14 09:40:25 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spiro S</AU>
<TI>A cost-effectiveness analysis of earwax softeners</TI>
<SO>Nurse Practitioner</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>8</NO>
<PG>28-31,166</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-05-14 09:40:34 +0100" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="PUB" ID="STD-Caballero-2005" MODIFIED="2008-05-14 09:40:34 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Caballero 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-14 09:40:34 +0100" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;Study author seriously ill - Dec 2005 - Feb 2007. Emailed me Oct 2007 saying now writing up paper and will let us know when it is completed.&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 09:40:34 +0100" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Caballero M, Navarrete P, Domenech J, Bernal-Sprekelsen M</AU>
<TI>Randomized clinical trial of clorobutanol, sodium carbonate, and irrigation in cerumen removal in adults</TI>
<SO>Proceedings of the XVIII IFOS World Congress</SO>
<YR>2005</YR>
<PG>Abstract No. F27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2008-05-14 09:40:45 +0100" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="PUB" ID="STD-Schroeder-2006" MODIFIED="2008-05-14 09:40:45 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Schroeder 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-05-14 09:40:45 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="OTHER">
<AU>Schroeder K</AU>
<TI>Controlled clinical trial of olive oil versus ear irrigation for the removal of ear wax in primary care (CLEAR)</TI>
<SO>National Research Register</SO>
<YR>2006</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="N0632169201"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-12 12:49:17 +0000" MODIFIED_BY="Jenny Bellorini">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-12 12:49:17 +0000" MODIFIED_BY="Jenny Bellorini">
<REFERENCE ID="REF-Anon-1971" NAME="Anon 1971" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Ear wax solvents compared</TI>
<SO>Drug and Therapeutics Bulletin</SO>
<YR>1971</YR>
<VL>9</VL>
<NO>4</NO>
<PG>15-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brister-1990" NAME="Brister 1990" TYPE="JOURNAL_ARTICLE">
<AU>Brister F, Fullwood HL, Ripp T, Blodgett C</AU>
<TI>Incidence of occlusion due to impacted cerumen among mentally retarded adolescents</TI>
<SO>American Journal of Mental Deficiency</SO>
<YR>1990</YR>
<VL>15</VL>
<PG>594-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1990" MODIFIED="2008-05-14 09:41:17 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Chalmers 1990" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers I, Adams M, Dickersin K, Hetherington J, Tarnow-Mordi W, Meinert C, et al</AU>
<TI>A cohort study of summary reports of controlled trials</TI>
<SO>JAMA</SO>
<YR>1990</YR>
<VL>263</VL>
<PG>1401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dinsdale-1991" NAME="Dinsdale 1991" TYPE="JOURNAL_ARTICLE">
<AU>Dinsdale RC, Roland PS, Manning SC</AU>
<TI>Catastrophic otologic injury from oral jet irrigation of the external auditory canal</TI>
<SO>Laryngoscope</SO>
<YR>1991</YR>
<VL>101</VL>
<PG>75-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Driver-1999" NAME="Driver 1999" TYPE="JOURNAL_ARTICLE">
<AU>Driver C</AU>
<TI>Removal or ear wax</TI>
<SO>Australian Family Physician</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>12</NO>
<PG>1215</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grossan-2000" MODIFIED="2008-05-14 09:41:29 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Grossan 2000" TYPE="JOURNAL_ARTICLE">
<AU>Grossan Murray M</AU>
<TI>Safe, effective techniques for cerumen removal</TI>
<SO>Geriatrics</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>1</NO>
<PG>80-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Handbook-2006" MODIFIED="2008-05-14 09:55:52 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Handbook 2006" TYPE="BOOK_SECTION">
<AU>Higgins J, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]</TI>
<SO>The Cochrane Library, Issue 2, 2008</SO>
<YR>2006</YR>
<PB>John Wiley and Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalantan-1999" MODIFIED="2008-05-14 09:44:00 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Kalantan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kalantan KA, Addulghani H, Al-Taweel AA, Al-Serhane AM</AU>
<TI>Use of cotton tipped swab and cerumen impaction</TI>
<SO>Indian Journal of Otolaryngology</SO>
<YR>1999</YR>
<VL>5,1</VL>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lewis_x002d_Cullinan-1990" NAME="Lewis-Cullinan 1990" TYPE="JOURNAL_ARTICLE">
<AU>Lewis-Cullinan C, Janken JK</AU>
<TI>The effect of cerumen removal on the hearing ability of geriatric patients</TI>
<SO>Journal of Advanced Nursing</SO>
<YR>1990</YR>
<VL>15</VL>
<PG>594-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Masterson-2000" NAME="Masterson 2000" NOTES="&lt;p&gt;Article is a review of trial by SInger 2000&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Masterson E, Seaton TL</AU>
<TI>How does liquid docusate sodium (Colace®) compare with triethanolamine polypeptide as a ceruminolytic for acute earwax removal?</TI>
<SO>Journal of Family Practice</SO>
<YR>December 2000</YR>
<VL>49</VL>
<NO>12</NO>
<PG>1076</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Minja-1996" NAME="Minja 1996" TYPE="JOURNAL_ARTICLE">
<AU>Minja BM, Machemba A</AU>
<TI>Prevalence of otitis media, hearing impairment and cerumen impaction among school children in rural and urban Dar es Salaam, Tanzania</TI>
<SO>International Journal of Paediatric Otorhinolaryngology</SO>
<YR>1996</YR>
<VL>37</VL>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prasad-1984" NAME="Prasad 1984" TYPE="JOURNAL_ARTICLE">
<AU>Prasad KS</AU>
<TI>Cardiac depression on syringing the ear</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>1984</YR>
<VL>98</VL>
<PG>1013</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-1989" NAME="Robinson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Robinson AC, Hawke M</AU>
<TI>The efficacy of ceruminoytics: everything old is new again</TI>
<SO>Journal of Otolaryngology</SO>
<YR>1989</YR>
<VL>18</VL>
<NO>6</NO>
<PG>263-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saloranta-2001" MODIFIED="2008-11-12 12:49:17 +0000" MODIFIED_BY="Jenny Bellorini" NAME="Saloranta 2001" TYPE="JOURNAL_ARTICLE">
<AU>Saloranta K, Westermarck T</AU>
<TI>Prevention of cerumen impaction by treatment of ear canal skin. A pilot randomized controlled study</TI>
<SO>Clinical Otolaryngology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>2</NO>
<PG>112-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seely-1996" NAME="Seely 1996" TYPE="JOURNAL_ARTICLE">
<AU>Seely DR, Quigley SM, Langmann AW</AU>
<TI>Ear candles - efficacy and safety</TI>
<SO>Laryngoscope</SO>
<YR>1996</YR>
<VL>106</VL>
<PG>1226-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharp-1990" MODIFIED="2008-05-14 09:44:23 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Sharp 1990" TYPE="JOURNAL_ARTICLE">
<AU>Sharp JF, Wilson JA, Ross L, Barr-Hamilton RM</AU>
<TI>Ear wax removal: a survey of current practice</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>301</VL>
<PG>1251-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swart-1995" NAME="Swart 1995" TYPE="JOURNAL_ARTICLE">
<AU>Swart SM, Lemmer R, Parbhoo JN, Prescolt CAJ</AU>
<TI>A survey of ear and hearing disorders amongst a representative sample of Grade 1 school children in Swaziland</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>1995</YR>
<VL>32</VL>
<PG>23-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zikk-1991" NAME="Zikk 1991" TYPE="JOURNAL_ARTICLE">
<AU>Zikk D, Rappaport Y, Himelfarb MZ</AU>
<TI>Invasive external otitis after removal of impacted cerumen by irrigation</TI>
<SO>New England Medical Journal</SO>
<YR>1991</YR>
<VL>325</VL>
<PG>969-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zivic-1993" NAME="Zivic 1993" TYPE="JOURNAL_ARTICLE">
<AU>Zivic RC, King S</AU>
<TI>Cerumen-impaction management for clients of all ages</TI>
<SO>Nurse Practitioner</SO>
<YR>1993</YR>
<VL>18</VL>
<NO>3</NO>
<PG>29-39</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-12 12:52:09 +0000" MODIFIED_BY="Jenny Bellorini">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-12 12:52:09 +0000" MODIFIED_BY="Jenny Bellorini" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-12 12:52:09 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Fahmy-1982a">
<CHAR_METHODS MODIFIED="2008-05-14 09:18:41 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Alternation, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-14 09:18:57 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Setting: hospital<BR/>Country: UK<BR/>Mean age: not known<BR/>% Female: not known<BR/>Duration: 7 days<BR/>Number randomised: 40 participants (80 ears)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exterol® (5% urea hydrogen peroxide in anhydrous glycerol) versus glycerol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Extent of wax dispersal; ease of wax dispersal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 12:52:09 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Quality score: C</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 12:52:00 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Fahmy-1982b">
<CHAR_METHODS>
<P>Alternation, not blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-14 09:19:15 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Setting: hospital ENT Department<BR/>Country: UK<BR/>Mean age: not known<BR/>% Female: not known<BR/>Duration: 7 days<BR/>Number randomised: 50 participants (100 ears)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exterol® (5% urea hydrogen peroxide in anhydrous glycerol) versus Cerumol® (2% paradichlorobenzene, 5% chlorbutol, and 10% turpentine oil, in arachis oil base)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-12 12:52:00 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Extent of wax dispersal; ease of wax dispersal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 12:51:57 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Quality score: C</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 12:51:50 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Fahmy-1982c">
<CHAR_METHODS>
<P>Alternation, not blind, multicentre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-14 09:19:37 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Setting: general practices<BR/>Country: UK<BR/>Mean age: not known<BR/>% Female: not known<BR/>Duration: 7 days<BR/>Number randomised: 160 participants (286 ears)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Exterol® (5% urea hydrogen peroxide in anhydrous glycerol) versus Cerumol® (2% paradichlorobenzene, 5% chlorbutol, and 10% turpentine oil, in arachis oil base)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Extent of wax dispersal; ease of wax dispersal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 12:51:50 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Quality score: C</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 12:51:41 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Jaffe-1978">
<CHAR_METHODS MODIFIED="2008-05-14 09:19:46 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Randomised, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-14 09:19:56 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Setting: 15 general practices<BR/>Country: UK<BR/>Mean age: n/a<BR/>% Female: 46<BR/>Duration: 3 days<BR/>Number randomised: 106 participants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cerumol® versus Otocerol®</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Impaction of wax scores; necessity for syringing; ease of syringing (where required)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 12:51:41 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Quality score: C</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 12:51:32 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Keane-1995">
<CHAR_METHODS MODIFIED="2008-05-14 09:20:16 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Randomised, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-14 09:20:27 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Setting: hospital<BR/>Country: Ireland<BR/>Mean age: n/a<BR/>% Female: n/a<BR/>Duration: 5 days<BR/>Number randomised: 97 participants (155 ears)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cerumol® (arachis oil 57.3%, chlorbutol 5%, paradichlorobenzene 2%) versus sodium bicarbonate (NaHCO3 5g, glycerol and purified water) versus sterile water versus no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Degree of wax removal without syringing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 12:51:32 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Quality score: B</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 12:51:24 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Lyndon-1992">
<CHAR_METHODS>
<P>Randomised, not blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-14 09:20:41 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Setting: general practice<BR/>Country: UK<BR/>Mean age: 52<BR/>% Female: 47<BR/>Duration: 5 days<BR/>Number randomised: 36 participants (72 ears)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Audax® (choline salicylate 20%, ethyleneoxide-polyoxypropylene glycol, glycol and glycerol) versus Earex® (arachis oil, almond oil, and rectified camphor oil)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Degree of wax impaction and need for syringing; ease of syringing; adverse effects; global impression of efficiency</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 12:51:24 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Quality score: C</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 12:51:14 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Meehan-2002">
<CHAR_METHODS MODIFIED="2008-05-14 09:20:50 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Randomised, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-14 09:21:05 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Setting: university paediatric emergency department<BR/>Country: USA<BR/>Mean age: 3.5<BR/>% Female: n/a<BR/>Duration: single treatment<BR/>Number randomised: 48 children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Colace® (docusate sodium) versus Cerumenex® (triethanolamine polypeptide) versus normal saline, with or without syringing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Extent of occlusion of tympanic membrane scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 12:51:14 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Quality score: A</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 12:51:09 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Singer-2000">
<CHAR_METHODS MODIFIED="2008-05-14 09:21:11 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Randomised, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 12:51:09 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Setting: university-based emergency department<BR/>Country: USA<BR/>Mean age: 40<BR/>% Female: 35<BR/>Duration: single treatment<BR/>Number randomised: 50 participants (50 ears)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Colace® (docusate sodium) versus Cerumenex® (triethanolamine polypeptide) with or without syringing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Extent of visualisation of tympanic membrane - after treatment alone; after syringing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 12:51:03 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Quality score: B</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 12:50:51 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Whatley-2003">
<CHAR_METHODS MODIFIED="2008-05-14 09:21:30 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Randomised, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-14 09:21:42 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Settings: urban tertiary care children's hospital emergency department and large general paediatric clinic, both in Louisville, USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Docusate sodium versus triethanolamine polypeptide versus saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Proportion of ears achieving complete visualisation of tympanic membrane - after treatment alone; after syringing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 12:50:51 +0000" MODIFIED_BY="Jenny Bellorini">
<P>Quality score: A</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-10-17 08:51:06 +0100" MODIFIED_BY="Jenny Bellorini" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:23:47 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Amjad-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:23:47 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, double-blinded<BR/>
<BR/>PARTICIPANTS<BR/>80 people (80 ears), most with hard or impacted cerumen<BR/>
<BR/>INTERVENTIONS<BR/>Cerumenex® + syringing versus carbamide peroxide + syringing<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:24:04 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Baker-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:24:04 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Non-randomised, not double-blinded nor placebo controlled<BR/>
<BR/>PARTICIPANTS<BR/>51 people (88 ears) with impacted wax<BR/>
<BR/>INTERVENTIONS<BR/>Single cerumenolytic agent (Xerumenex®)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:24:24 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Burgess-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:24:24 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, double-blinded<BR/>
<BR/>PARTICIPANTS<BR/>50 people (74 ears) with more than one-half occlusion of an ear with wax<BR/>
<BR/>INTERVENTIONS<BR/>Dioctyl-medo® ear drops (5% dioctyl sodium sulphosuccinate in a maize oil base) + syringing versus maize oil + syringing<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:24:31 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Carr-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:24:31 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, double-blinded<BR/>
<BR/>PARTICIPANTS<BR/>69 people with cerumen occluding at least one external auditory canal<BR/>
<BR/>INTERVENTIONS<BR/>10% aqueous sodium bicarbonate versus 2.5% aqueous acetic acid<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure addressed, but data not usable - results given only as average change.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:24:47 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-de-Saintonge-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:24:47 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, double-blinded<BR/>
<BR/>PARTICIPANTS<BR/>67 ears, unstated number of participants<BR/>
<BR/>INTERVENTIONS<BR/>Xerumenex® (triethanolamine polypeptide oleate condensate) + syringing versus olive oil + syringing<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-17 08:51:06 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Dubow-1959">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-17 08:51:06 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, double-blinded<BR/>
<BR/>PARTICIPANTS<BR/>60 children with at least one completely cerumen-occluded ear canal<BR/>
<BR/>INTERVENTIONS<BR/>Drops (peroxide, Cerumenex® or mineral oil) plus syringing</P>
<P>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed?</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:26:59 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Dummer-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:26:59 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, single-blinded (investigator)<BR/>
<BR/>PARTICIPANTS<BR/>50 people (100 ears) with hardened or impacted ear wax<BR/>
<BR/>INTERVENTIONS<BR/>Audax® (choline salicylate and polyoxypropylene glycol condensate in glycerin and propylene glycerol) verus Cerumol® (turpentine 10%, chlorbutol 5%, paradichlorobenzene 2%, arachis oil 57.3%)<BR/>
<BR/>OUTCOMES<BR/>Primary outcome addressed, but not possible to extract necessary data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:27:11 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Eekhof-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:27:11 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Quasi-randomised (alternation), not blinded<BR/>
<BR/>PARTICIPANTS<BR/>42 people with persistent ear wax<BR/>
<BR/>INTERVENTIONS<BR/>Olive oil + syringing versus water + syringing<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:27:28 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Fraser-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:27:28 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, double-blinded<BR/>
<BR/>PARTICIPANTS<BR/>62 geriatric patients with hard wax completely occluding the external auditory meatus of both ears<BR/>
<BR/>INTERVENTIONS<BR/>Cerumol® (turpentine oil 10%, chlorbutol 5%, paradichlorobenzene 2%, arachis oil 57.3%) versus sodium bicarbonate; olive oil versus sodium bicarbonate; Waxsol® (docusate sodium) versus sodium bicarbonate; Xerumenex® (triethanolamine polypeptide oleate 10% in propylene glycerol) versus sodium bicarbonate; Dioctyl® (docusate sodium in corn oil) versus sodium bicarbonate. All treatments were followed by a series of syringing attempts.<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:27:42 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-GPRG-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:27:42 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, double-blinded<BR/>
<BR/>PARTICIPANTS<BR/>150 people with hard or impacted cerumen<BR/>
<BR/>INTERVENTIONS<BR/>Dioctyl-medo® ear drops (5% dioctyl sodium sulphosuccinate in a maize oil base) + syringing versus maize oil + syringing<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:27:52 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-GPRG-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:27:52 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, double-blinded<BR/>
<BR/>PARTICIPANTS<BR/>107 people with hard or impacted cerumen<BR/>
<BR/>INTERVENTIONS<BR/>Waxsol® (dioctyl sodium sulphosuccinate) versus Cerumol® (turpentine oil 10%, chlorbutol 5%, paradichlorobenzene 2%, arachis oil 57.3%) + syringing versus maize oil + syringing<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:28:07 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Hewitt-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:28:07 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, not blinded<BR/>
<BR/>PARTICIPANTS<BR/>All 31 participants presented with ear pain, and majority with acute otitis media</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hinchcliffe-1955">
<CHAR_REASON_FOR_EXCLUSION>
<P>ALLOCATION<BR/>Non-randomised, double-blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:28:23 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Pavlidis-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:28:23 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, non-blinded<BR/>
<BR/>PARTICIPANTS<BR/>39 ears (of 26 patients) 'partially or completely occluded by ear wax'<BR/>
<BR/>INTERVENTIONS<BR/>Warm tap water instilled into the ear as a softening agent 15 minutes before syringing versus syringing alone<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Proudfoot-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>ALLOCATION<BR/>Non-randomised, not blinded<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:28:37 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Roland-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:28:37 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Randomised, double-blinded<BR/>
<BR/>PARTICIPANTS<BR/>74 company (sponsor) employees with 'excessive or impacted cerumen'<BR/>
<BR/>INTERVENTIONS<BR/>Cerumenex® (10% triethanolamine polypeptide oleate-condensate) versus Murine® (6.5% carbamide peroxide) versus placebo (saline solution). All treatments were followed by a standardised irrigation procedure<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-14 09:28:54 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Spiro-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-14 09:28:54 +0100" MODIFIED_BY="Jenny Bellorini">
<P>ALLOCATION<BR/>Quasi-randomised (sequential), not blinded<BR/>
<BR/>PARTICIPANTS<BR/>302 people with hard or impacted cerumen<BR/>
<BR/>INTERVENTIONS<BR/>Colace® (docusate sodium) + syringing versus mineral oil + syringing versus no treatment + syringing versus syringing + 50% vinegar - 50% alcohol solution<BR/>
<BR/>OUTCOMES<BR/>Primary outcome measure (assessment of extent of cerumen removal prior to syringing) not addressed<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-10-17 08:52:37 +0100" MODIFIED_BY="Jenny Bellorini" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2008-10-17 08:52:37 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Caballero-2005">
<CHAR_METHODS MODIFIED="2008-10-17 08:52:27 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-17 08:51:44 +0100" MODIFIED_BY="Jenny Bellorini">
<P>90 adults with total cerumen obstruction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-17 08:52:19 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Instillation of trademarked product containing chlorobutanol or sodium carbonate, or normal saline as control 15 minutes prior to syringing<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-17 08:52:37 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Proportion of the tympanic membrane visualised after irrigation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-17 08:52:06 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Information available from abstract only</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-11-12 12:50:21 +0000" MODIFIED_BY="Jenny Bellorini" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-11-12 12:50:21 +0000" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Schroeder-2006">
<CHAR_STUDY_NAME MODIFIED="2008-05-14 09:29:42 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Controlled clinical trial of olive oil versus ear irrigation for the removal of ear wax in primary care (CLEAR)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-05-14 09:30:10 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Randomised controlled trial. Random allocation to: <BR/>[A] self-administered olive oil for 21 days;<BR/>[B] usual care.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 12:50:21 +0000" MODIFIED_BY="Jenny Bellorini">
<P>The total sample size will be 330 participants, with 165 individuals in both the intervention and control groups.</P>
<P>Inclusion criteria: Participants will be included if they present with ear wax that completely occludes and obstructs the ear canal in one or both ears (with or without symptoms of, for example, blockage, irritation or loss of hearing).</P>
<P>Exclusion criteria: partial occlusion of the ear canal (ear syringing would not be indicated); people for whom ear irrigation is contraindicated, e.g. pain, ear infection in past four weeks, pain or discharge from affected ear in past month, ear to be syringed is only hearing ear, infection, history of perforated tympanic membrane ; refusal to give informed consent ; inability to administer ear drops to external ear canal (for example those with severe joint disease)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-14 09:31:31 +0100" MODIFIED_BY="Jenny Bellorini">
<P>To investigate if the use of olive oil alone for a total of 3 weeks is as effective as usual care - i.e. olive oil for 5 days followed by ear irrigation - for the removal of ear wax in primary care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-14 09:32:12 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Primary outcomes: <BR/>i) proportion of individuals with sufficient clearance of the ear canal from wax to allow visualising the ear drum of at least one ear 16 days after randomisation (which makes a total of 5 + 16 = 21 days of olive oil use); <BR/>ii) proportion of ears with sufficient clearance of the ear canal from wax 16 days after randomisation.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-05-14 09:32:23 +0100" MODIFIED_BY="Jenny Bellorini">
<P>01/08/2005 to 31/07/2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-05-14 09:32:39 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Dr K Schroeder, Academic Unit of Primary Health Care, University of Bristol, Cotham House, Cotham Hill, Bristol BS6 6JL. Telephone: +44 (0) 117 954 5508. Fax: +44 (0) 117 954 6677. E-mail: k.schroeder@bristol.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-04-30 11:47:53 +0100" MODIFIED_BY="[Empty name]">
<P>Publication ID: N0632169201</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fahmy-1982a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fahmy-1982b">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fahmy-1982c">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jaffe-1978">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Keane-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lyndon-1992">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Meehan-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Singer-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Whatley-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-17 08:53:02 +0100" MODIFIED_BY="Jenny Bellorini">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-17 08:53:02 +0100" MODIFIED_BY="Jenny Bellorini" NO="1">
<TITLE MODIFIED="2008-10-17 08:53:02 +0100" MODIFIED_BY="Jenny Bellorini">Studies and interventions</TITLE>
<TABLE COLS="5" ROWS="36">
<TR>
<TD COLSPAN="3">
<P>Comparison</P>
</TD>
<TD>
<P>Study</P>
</TD>
<TD>
<P>Grade</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>A: Active treatment versus no treatment</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sterile water</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Nothing</P>
</TD>
<TD>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD>
<P>Sodium bicarbonate</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Nothing</P>
</TD>
<TD>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD>
<P>Chlorambutol (Cerumol®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Nothing</P>
</TD>
<TD>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>B: Active treatment versus water or saline 'placebo'</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Chlorambutol (Cerumol®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Water</P>
</TD>
<TD>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD>
<P>Sodium bicarbonate</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Water</P>
</TD>
<TD>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Docusate sodium (Colace®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Saline</P>
</TD>
<TD>
<P>
<LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>
</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD>
<P>Triethanolamine (Cerumenex®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Saline</P>
</TD>
<TD>
<P>
<LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>
</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Docusate sodium</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Saline</P>
</TD>
<TD>
<P>
<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>
</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD>
<P>Triethanolamine</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Saline</P>
</TD>
<TD>
<P>
<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>
</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>C: Head-to-head comparisons of active treatments</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Chlorambutol (Cerumol®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Almond oil (Otocerol®)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Jaffe-1978" TYPE="STUDY">Jaffe 1978</LINK>
</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hydrogen peroxide (Exterol®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Glycerol</P>
</TD>
<TD>
<P>
<LINK REF="STD-Fahmy-1982a" TYPE="STUDY">Fahmy 1982a</LINK>
</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hydrogen peroxide (Exterol®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Chlorambutol (Cerumol®)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Fahmy-1982b" TYPE="STUDY">Fahmy 1982b</LINK>
</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hydrogen peroxide</P>
<P>(Exterol®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Chlorambutol (Cerumol®)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Fahmy-1982c" TYPE="STUDY">Fahmy 1982c</LINK>
</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sodium bicarbonate</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Chlorambutol (Cerumol®)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Keane-1995" TYPE="STUDY">Keane 1995</LINK>
</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Choline salicylate (Audax®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Almond oil (Earex®)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Lyndon-1992" TYPE="STUDY">Lyndon 1992</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Docusate sodium (Colace®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Triethanolamine (Cerumenex®)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Meehan-2002" TYPE="STUDY">Meehan 2002</LINK>
</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Docusate sodium (Colace®)</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Triethanolamine (Cerumenex®)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Singer-2000" TYPE="STUDY">Singer 2000</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Docusate sodium</P>
</TD>
<TD>
<P>vs.</P>
</TD>
<TD>
<P>Triethanolamine </P>
</TD>
<TD>
<P>
<LINK REF="STD-Whatley-2003" TYPE="STUDY">Whatley 2003</LINK>
</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-12 12:49:03 +0000" MODIFIED_BY="Jenny Bellorini">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-12 12:49:03 +0000" MODIFIED_BY="Jenny Bellorini" NO="1">
<NAME>'Active drops' versus saline: triethanolamine polypeptide (Cerumenex) versus saline in children</NAME>
<DICH_OUTCOME CHI2="0.02330574588999529" CI_END="12.043265242857442" CI_START="1.1796951330582515" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.7692680182136855" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.08074425143168" LOG_CI_START="0.07176978769826341" LOG_EFFECT_SIZE="0.5762570195649718" METHOD="PETO" NO="1" P_CHI2="0.878664689521252" P_Q="1.0" P_Z="0.02516932074544708" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="44" WEIGHT="100.0" Z="2.2387940325200355">
<NAME>Syringing not necessary</NAME>
<GROUP_LABEL_1>Cerumenex</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cerumenex</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.38315906773903" CI_START="0.8980644803884555" EFFECT_SIZE="4.063159139889475" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2644201451239243" LOG_CI_START="-0.04669248017951262" LOG_EFFECT_SIZE="0.6088638324722059" ORDER="2559" O_E="2.3636363636363633" SE="0.7701540462154053" STUDY_ID="STD-Meehan-2002" TOTAL_1="17" TOTAL_2="16" VAR="1.6859504132231407" WEIGHT="59.22162918725221"/>
<DICH_DATA CI_END="20.840954892298242" CI_START="0.5481355303436161" EFFECT_SIZE="3.379891693938916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.318917613617665" LOG_CI_START="-0.2611120458897553" LOG_EFFECT_SIZE="0.5289027838639548" ORDER="2560" O_E="1.4137931034482758" SE="0.9281172432676131" STUDY_ID="STD-Whatley-2003" TOTAL_1="30" TOTAL_2="28" VAR="1.1608986795168659" WEIGHT="40.77837081274778"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3991435049569573" CI_END="1.4822757994431592" CI_START="0.19733764474284296" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5408408408408408" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.1709290181050704" LOG_CI_START="-0.7047900594786436" LOG_EFFECT_SIZE="-0.2669305206867865" METHOD="MH" MODIFIED="2008-05-09 14:29:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5275323334089801" P_Q="0.0" P_Z="0.23214768227864113" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="41" WEIGHT="99.99999999999999" Z="1.1948448316648965">
<NAME>Wax cleared after 1st irrigation</NAME>
<GROUP_LABEL_1>Cerumenex</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cerumenex</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9689270669505867" CI_START="0.025989353085191413" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.472599529084777" LOG_CI_START="-1.5852045306193514" LOG_EFFECT_SIZE="-0.5563025007672873" MODIFIED="2008-05-09 13:53:23 +0100" MODIFIED_BY="[Empty name]" ORDER="2561" O_E="0.0" SE="1.208764290964583" STUDY_ID="STD-Meehan-2002" TOTAL_1="10" TOTAL_2="14" VAR="1.4611111111111112" WEIGHT="28.648648648648646"/>
<DICH_DATA CI_END="2.006556437780437" CI_START="0.20827549689603597" EFFECT_SIZE="0.6464646464646465" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.3024513795056463" LOG_CI_START="-0.6813618207329718" LOG_EFFECT_SIZE="-0.18945522061366268" MODIFIED="2008-05-09 14:29:11 +0100" MODIFIED_BY="[Empty name]" ORDER="2562" O_E="0.0" SE="0.577896743774047" STUDY_ID="STD-Whatley-2003" TOTAL_1="26" TOTAL_2="27" VAR="0.33396464646464646" WEIGHT="71.35135135135134"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-11-12 12:48:56 +0000" MODIFIED_BY="Jenny Bellorini" NO="2">
<NAME>'Active drops' versus saline - docusate sodium (Colace) versus saline in children</NAME>
<DICH_OUTCOME CHI2="0.5217530977477349" CI_END="7.463887118570687" CI_START="0.48499449075141593" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9026150772285089" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.8729650626579816" LOG_CI_START="-0.31426319469639385" LOG_EFFECT_SIZE="0.2793509339807939" METHOD="PETO" NO="1" P_CHI2="0.4700948856461392" P_Q="1.0" P_Z="0.3563480038338266" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="44" WEIGHT="100.0" Z="0.9223462569364266">
<NAME>Syringing not necessary</NAME>
<GROUP_LABEL_1>Colace</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Colace</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.489401076436875" CI_START="0.13597286506595058" EFFECT_SIZE="1.0743966618791623" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9288770520374007" LOG_CI_START="-0.8665477513938786" LOG_EFFECT_SIZE="0.031164650321761064" ORDER="2563" O_E="0.06451612903225801" SE="1.054641417031646" STUDY_ID="STD-Meehan-2002" TOTAL_1="15" TOTAL_2="16" VAR="0.8990634755463061" WEIGHT="43.72542187266663"/>
<DICH_DATA CI_END="18.344448068640634" CI_START="0.4796002068687954" EFFECT_SIZE="2.9661424592581396" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2635046496242819" LOG_CI_START="-0.31912063824633957" LOG_EFFECT_SIZE="0.47219200568897124" ORDER="2564" O_E="1.2580645161290325" SE="0.9296419282167252" STUDY_ID="STD-Whatley-2003" TOTAL_1="34" TOTAL_2="28" VAR="1.1570938742089014" WEIGHT="56.27457812733336"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5837148391249022" CI_END="1.3443064340943591" CI_START="0.1909830006843805" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5066948555320648" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.1284982772498218" LOG_CI_START="-0.7190052873990045" LOG_EFFECT_SIZE="-0.2952535050745914" METHOD="MH" MODIFIED="2008-05-09 14:29:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4448600340017319" P_Q="0.0" P_Z="0.17205654109525648" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="41" WEIGHT="99.99999999999999" Z="1.3656254920773085">
<NAME>Wax cleared after 1st irrigation</NAME>
<GROUP_LABEL_1>Colace</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Colace</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3895248388658525" CI_START="0.021616386539216572" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.378311549326915" LOG_CI_START="-1.66521690229929" LOG_EFFECT_SIZE="-0.6434526764861874" MODIFIED="2008-05-09 13:55:06 +0100" MODIFIED_BY="[Empty name]" ORDER="2565" O_E="0.0" SE="1.200378728114211" STUDY_ID="STD-Meehan-2002" TOTAL_1="12" TOTAL_2="14" VAR="1.440909090909091" WEIGHT="29.45736434108527"/>
<DICH_DATA CI_END="1.8634249594331822" CI_START="0.2085398784669304" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.27031190829979856" LOG_CI_START="-0.6808108838935879" LOG_EFFECT_SIZE="-0.20524948779689467" MODIFIED="2008-05-09 14:29:00 +0100" MODIFIED_BY="[Empty name]" ORDER="2566" O_E="0.0" SE="0.5586942362681484" STUDY_ID="STD-Whatley-2003" TOTAL_1="30" TOTAL_2="27" VAR="0.31213924963924966" WEIGHT="70.54263565891472"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-05-14 09:45:41 +0100" MODIFIED_BY="Jenny Bellorini" NO="3">
<NAME>Alternative 'active' drops - triethanolamine polypeptide (Cerumenex) versus docusate sodium (Colace) - children</NAME>
<DICH_OUTCOME CHI2="1.8669977791965426" CI_END="5.109401913294723" CI_START="0.6160980078315952" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7742300696335351" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="46.438072335021886" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.70837006628782" LOG_CI_START="-0.21035019550645084" LOG_EFFECT_SIZE="0.24900993539068447" METHOD="PETO" NO="1" P_CHI2="0.17181952190008265" P_Q="1.0" P_Z="0.28802816767495776" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="1.0624572581107974">
<NAME>Syringing not necessary</NAME>
<GROUP_LABEL_1>Cerumenex</GROUP_LABEL_1>
<GROUP_LABEL_2>Colace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colace</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cerumenex</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.361388582045088" CI_START="0.8305959945869217" EFFECT_SIZE="3.7974069859199666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2395844575572232" LOG_CI_START="-0.08061016753506424" LOG_EFFECT_SIZE="0.5794871450110795" ORDER="2567" O_E="2.21875" SE="0.7754888578480001" STUDY_ID="STD-Meehan-2002" TOTAL_1="17" TOTAL_2="15" VAR="1.6628339213709677" WEIGHT="48.42734598388354"/>
<DICH_DATA CI_END="3.7873857203560433" CI_START="0.19908389927447476" EFFECT_SIZE="0.8683360624003511" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5783395374133228" LOG_CI_START="-0.7009638617154174" LOG_EFFECT_SIZE="-0.06131216215104729" ORDER="2568" O_E="-0.25" SE="0.7514691493021793" STUDY_ID="STD-Whatley-2003" TOTAL_1="34" TOTAL_2="30" VAR="1.7708333333333333" WEIGHT="51.57265401611645"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010622694768677207" CI_END="3.067373501420864" CI_START="0.36629328271158207" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0599803343166174" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.4867666614503257" LOG_CI_START="-0.43617104559437525" LOG_EFFECT_SIZE="0.025297807927975268" METHOD="MH" MODIFIED="2008-05-09 14:29:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9179102267730443" P_Q="0.0" P_Z="0.9144354896253466" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="42" WEIGHT="100.0" Z="0.10744558825190988">
<NAME>Wax cleared after 1st irrigation</NAME>
<GROUP_LABEL_1>Cerumenex</GROUP_LABEL_1>
<GROUP_LABEL_2>Colace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colace</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cerumenex</GRAPH_LABEL_2>
<DICH_DATA CI_END="22.40090884701931" CI_START="0.0666860068355038" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.3502656388358711" LOG_CI_START="-1.1759652873980708" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2008-05-09 14:09:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2569" O_E="0.0" SE="1.483920551114581" STUDY_ID="STD-Meehan-2002" TOTAL_1="10" TOTAL_2="12" VAR="2.202020202020202" WEIGHT="12.389380530973453"/>
<DICH_DATA CI_END="3.247911310094815" CI_START="0.3311192066248761" EFFECT_SIZE="1.037037037037037" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.5116041615598051" LOG_CI_START="-0.48001562719334134" LOG_EFFECT_SIZE="0.015794267183231882" MODIFIED="2008-05-09 14:29:38 +0100" MODIFIED_BY="[Empty name]" ORDER="2570" O_E="0.0" SE="0.5824823725107174" STUDY_ID="STD-Whatley-2003" TOTAL_1="26" TOTAL_2="30" VAR="0.33928571428571425" WEIGHT="87.61061946902655"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-05-09 14:29:39 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-04-28 13:14:58 +0100" MODIFIED_BY="Carolyn Doree" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 'Active drops' vs. saline: Triethanolamine polypeptide (Cerumenex) vs. saline in children, outcome: 1.1 Syringing not necessary.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArsAAACgCAMAAAA7M1TBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-05-09 14:29:12 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 'Active drops' vs. saline: Triethanolamine polypeptide (Cerumenex) vs. saline in children, outcome: 1.2 Wax cleared after 1st irrigation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAACgCAMAAAAhD7RPAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-04-28 13:15:33 +0100" MODIFIED_BY="Carolyn Doree" NO="3" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 'Active drops' vs saline - Docusate sodium (Colace) vs. saline in children, outcome: 2.1 Syringing not necessary.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAACgCAMAAADzX74XAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-05-09 14:29:01 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-002.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 'Active drops' vs saline - Docusate sodium (Colace) vs. saline in children, outcome: 2.2 Wax cleared after 1st irrigation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAACgCAMAAADpY16ZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2008-04-28 13:15:50 +0100" MODIFIED_BY="Carolyn Doree" NO="5" REF_ID="CMP-003.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Alternative 'active' drops - Triethanolamine polypeptide (Cerumenex) vs. docusate sodium (Colace)- children, outcome: 3.1 Syringing not necessary.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsAAAACgCAMAAAA1miquAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2008-05-09 14:29:39 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-003.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Alternative 'active' drops - Triethanolamine polypeptide (Cerumenex) vs. docusate sodium (Colace)- children, outcome: 3.2 Wax cleared after 1st irrigation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArwAAACgCAMAAADZ70+4AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-12 12:48:30 +0000" MODIFIED_BY="Jenny Bellorini">
<APPENDIX ID="APP-01" MODIFIED="2008-11-12 12:48:30 +0000" MODIFIED_BY="Jenny Bellorini" NO="1">
<TITLE MODIFIED="2008-05-13 11:17:50 +0100" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-12 12:48:30 +0000" MODIFIED_BY="Jenny Bellorini">
<TABLE COLS="2" ROWS="2">
<TR>
<TH VALIGN="BOTTOM">
<P>CENTRAL</P>
</TH>
<TH VALIGN="BOTTOM">
<P>MEDLINE, EMBASE and CINAHL (Dialog DataStar)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1. CERUMEN (MeSH term)<BR/>2. CERUM*<BR/>3. (EAR* and WAX*)<BR/>4. EARWAX* OR (EAR* NEAR IMPACTED) OR (EAR* NEAR IMPACTION)<BR/>5. (#1 OR #2 OR #3 OR #4)</P>
</TD>
<TD VALIGN="TOP">
<P>1. CERUMEN.DE.<BR/>2. CERUM$2.TI,AB.<BR/>3. ((EAR$1 AND WAX$1) OR (EAR$1 NEAR IMPACTED) OR (EAR$1 NEAR IMPACTION)).TI,AB.<BR/>4. EARWAX$2.TI,AB.<BR/>5. 1 OR 2 OR 3 OR 4</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>